Logo
x

Search category

Subscribe Now

Amgen

Amgen Reported Results of ENZ110 (biosimilar, romiplostim) for the Treatment of Chronic Immune Thrombocytopenia

Amgen Reported Results of ENZ110 (biosimilar, romiplostim) for the Treatment of Chronic Immune Thrombocytopenia

  • July 10, 2023
Amgen Files BPCIA Complaint Against Sandoz Over Denosumab Biosimilar

Amgen Files BPCIA Complaint Against Sandoz Over Denosumab Biosimilar

  • May 10, 2023
Amgen Entered into a Multi-Year Collaboration Agreement with Tscan Therapeutics to Identify Novel Targets for Crohn's Disease

Amgen Entered into a Multi-Year Collaboration Agreement with Tscan Therapeutics to Identify Novel Targets for Crohn's Disease

  • May 10, 2023
Amgen Reports Real-World Study Results of Prolia (denosumab) for Osteoporosis Associated with High Fracture Risk

Amgen Reports Real-World Study Results of Prolia (denosumab) for Osteoporosis Associated with High Fracture Risk

  • May 9, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
Amgen Launches First Humira (adalimumab) Biosimilar Amjevita in the US

Amgen Launches First Humira (adalimumab) Biosimilar Amjevita in the US

  • February 1, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.